FDA approves Roche's Wilserdly with everolimus for ESR1-mutated advanced breast cancer
Roche says the US regulator cleared giredestrant plus everolimus after prior endocrine therapy, with a separate adjuvant application due a decision on 30 November 2026.
Roche announced on 16 November 2026 that the US Food and Drug Administration has approved Wilserdly (giredestrant), an oral selective oestrogen receptor degrader (SERD), in combination with everolimus. The indication covers adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer who have previously received endocrine therapy.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release: Roche ↗
Article written by VigiEye from the official source (Roche). Claims are the company's own. AI-assisted; check the source before acting.